BD, a prominent global medical technology company, has recently obtained FDA 510(k) clearance for its groundbreaking blood collection device—the BD MiniDraw™ Capillary Blood Collection System. This innovative system facilitates less invasive blood sample collection through a fingerstick, delivering lab-quality results for commonly requested blood tests. Notably, it eliminates the necessity for conventional venous blood draws and can be administered by trained healthcare personnel without the presence of a phlebotomist.
Distinguished by its unique design, the BD MiniDraw™ System ensures lab-quality results with a substantially reduced blood volume compared to traditional venous collections. The FDA clearance encompasses low-volume blood collection for essential tests, including a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing—critical for diagnosing and monitoring chronic conditions like hypertension and high cholesterol.
A key advantage of the BD MiniDraw™ System is its potential to revolutionize the blood testing experience. By expanding access to blood collection in non-traditional sites such as retail pharmacies, the system contributes to enhanced health equity and patient accessibility. This approach enables patients to undergo blood collection in familiar and convenient locations, improving overall patient experience and potentially boosting adherence to recommended blood tests.
BD envisions the future expansion of blood tests facilitated by the MiniDraw™ System, offering the possibility of a broader spectrum of diagnostic testing at easily accessible locations. The system is poised to bring transformative changes to the conventional blood testing process, benefiting patients, healthcare providers, and collection sites. The convenience of capillary collection with the BD MiniDraw™ System has the potential to increase patient adherence, facilitate earlier diagnosis, and improve monitoring of chronic conditions, thereby contributing to overall advancements in healthcare outcomes.